Abstract
A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for antiadipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
Keywords: Hydrazone derivatives, Anti-oxidant, Anti-dyslipidemic, Atherosclerosis, Lipid, Anti-hyperglycemic.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity
Volume: 18 Issue: 26
Author(s): Kanika Varshney, Amit K. Gupta, Ravi Sonkar, Salil Varshney, Akanksha Mishra, Geetika Bhatia, Anil Gaikwad, Arvind Kumar Srivastava, Mridula Saxena, Sudha Jain*Anil K. Saxena*
Affiliation:
- Department of Chemistry, Lucknow University, Lucknow, 226007,India
- Medicinal & Process Chemistry Division, Central Drug Research Institute, Lucknow, 226031,India
Keywords: Hydrazone derivatives, Anti-oxidant, Anti-dyslipidemic, Atherosclerosis, Lipid, Anti-hyperglycemic.
Abstract: A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for antiadipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
Export Options
About this article
Cite this article as:
Varshney Kanika , Gupta K. Amit , Sonkar Ravi , Varshney Salil , Mishra Akanksha, Bhatia Geetika , Gaikwad Anil , Srivastava Kumar Arvind , Saxena Mridula, Jain Sudha*, Saxena K. Anil *, Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity, Current Topics in Medicinal Chemistry 2018; 18 (26) . https://dx.doi.org/10.2174/1568026619666181220112903
DOI https://dx.doi.org/10.2174/1568026619666181220112903 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer’s Disease
Current Alzheimer Research Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Circadian Rhythm of Blood Pressure in Diabetes Mellitus: Evidence, Mechanisms and Implications
Current Diabetes Reviews Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - Second Part: Guidelines
Current Hypertension Reviews The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility
Current Pharmaceutical Design Self-care improvement after a pharmaceutical intervention in elderly type 2 diabetic patients
Current Diabetes Reviews Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Current Pharmaceutical Design The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design